Repatha is a prescription medication used to lower LDL cholesterol and reduce the risk of cardiovascular events such as heart attack and stroke [1]. It is a PCSK9 inhibitor, which works by increasing the liver's ability to remove LDL cholesterol from the blood [2].
How does Repatha work?
Repatha, also known by its generic name evolocumab, is an injectable medication that targets and inhibits the PCSK9 protein [3]. PCSK9 normally attaches to LDL receptors on the liver, marking them for degradation. By blocking PCSK9, Repatha allows more LDL receptors to remain on the liver's surface, leading to increased clearance of LDL cholesterol from the bloodstream [2][4].
What conditions does Repatha treat?
Repatha is approved to treat adults with high levels of LDL cholesterol (often referred to as "bad" cholesterol) who have cardiovascular disease or are at high risk of developing it [1]. It is also used for adults with genetic high cholesterol conditions, such as heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) [1][5]. It is typically used in conjunction with diet and other cholesterol-lowering medications, like statins, when those alone are not sufficient [1].
When does Repatha patent expiry happen?
The patent landscape for Repatha is complex. Drug patent information can be found on resources like DrugPatentWatch.com, which tracks patent expirations and exclusivity periods for pharmaceuticals [6]. While specific patent expiry dates can vary due to multiple patents covering different aspects of a drug, including its formulation and method of use, the primary patents for Repatha are expected to expire in the coming years, potentially opening the door for generic competition [6].
Can biosimilars of Repatha be developed?
Yes, the development of biosimilars for biologic drugs like Repatha is possible after patent and exclusivity protections expire [7]. Biosimilars are highly similar to an already approved biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency [7]. The availability of biosimilars can increase competition and potentially lower treatment costs [7].
What are the side effects associated with Repatha?
Common side effects of Repatha include injection site reactions, influenza, upper respiratory tract infections, and nasopharyngitis (common cold symptoms) [1]. Serious side effects are rare but can include allergic reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How much does Repatha cost?
The cost of Repatha can vary significantly based on insurance coverage, pharmacy, and geographic location [8]. It is generally considered a high-cost medication, reflecting its innovative biologic nature and development expenses [8]. Many patients utilize manufacturer savings programs or insurance to help manage out-of-pocket expenses [8].
Who manufactures Repatha?
Repatha is manufactured by Amgen Inc. [9].
---
Sources:
1. Repatha Prescribing Information. Amgen Inc.
2. Scott, R., et al. (2012). PCSK9 inhibition and cardiovascular disease: implications for the future. European Heart Journal, 33(9), 1167-1177.
3. Sabatine, M. S., et al. (2015). Cardiovascular benefit of PCSK9 inhibition with evolocumab. New England Journal of Medicine, 373(11), 1030-1039.
4. Zhang, D. W., et al. (2013). PCSK9 inhibition and LDL cholesterol reduction: effects on low-density lipoprotein receptor function. Journal of Lipid Research, 54(5), 1252-1261.
5. Familial Hypercholesterolemia Foundation. (n.d.). FH Treatments.
6. DrugPatentWatch.com. (n.d.). Repatha patent information. https://drugpatentwatch.com/
7. U.S. Food and Drug Administration. (n.d.). Biosimilars.
8. GoodRx. (n.d.). Repatha Prices, Coupons & Patient Assistance Programs.
9. Amgen Inc. (n.d.). Our Medicines.